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THE PRESENT STATUS OF TOCOPHEROL AND CALCIUM
FOR PROPHYLAXIS OF POSTOPERATIVE
PHLEBOTHROMBOSIS*
JOHN H. KAY**
Since the publication of the early in vitro experiments with tocopherol,2"
I have published, with others, reports on the clinical use of what we have
called an antithrombin test and on the use of tocopherol and calcium as
prophylactic agents in postoperative thrombosis.8'" Since we originally had
no concept of the course the clinical work would follow, certain statements
which are contradictory appear in these earlier articles as they are read
in chronological order. It is the purpose of this article to clarify certain
of these statements and to attempt to define the phenomenon which we
measure by the antithrombin test.
In the evaluation of any work, it seems reasonable that it should be
broken down into its component parts and that these should be evaluated
separately before the whole is accepted or discarded. Our clinical work
on phlebothrombosis has consisted of three parts. One part is the evaluation
of the antithrombin test as an indicator of a prethrombotic state. The
second part concerns'the effect of alpha tocopherol and calcium on anti-
thrombin levels. The third part concerns the effect of alpha tocopherol and
calcium on the incidence of intravascular clotting. Our data will be con-
sidered from these three aspects.
Certain basic data must be mentioned before the antithrombin test which
we have devised is described. In our first paper on the ability of alpha
tocopherol to inhibit thrombin, the statement was made that "practically no
antithrombic activity remains in the supernatant fluid" after precipitation
of the disodium salt of alpha tocopherol (25 mg.) by 0.1 ml. of 1 per cent
CaCl2. Subsequently we published studies on the use of calcium and toco-
pherol to increase the ability of plasma to inhibit thrombin. In our in vitro
work in which we were dealing with thrombin in amounts of from 2 to 150
units, we found that the calcium salt of alpha tocopherol is only able to
inhibit 0.06 units of thrombin. However, in dealing with plasma, we found
that it requires only 0.06 units of thrombin to produce clotting in all normal
plasmas. An amount of inhibitor which can be regarded as practically none
in the first instance thus becomes of great significance when one is dealing
with plasma.
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It should be emphasized again that there is a 1 :1 relationship between
the concentration of fibrinogen and the antithrombic activity of the sodium
salts of alpha tocopherol. Thus it is necessary to add 5 mg. of the disodium
salt of alpha tocopherol to plasma before a measurable increase in the ability
of plasma to inhibit thrombin is noted. On the other hand, mere traces of
the calcium salt of alpha tocopherol raise the level of plasma to maximum
normal levels.
Further misunderstanding (which I did not anticipate) has arisen from
an attempt by some observers to carry over the in vitro work to the in vivo
interpretation of these phenomena. This is not justified. In working with
the alpha globulin thrombin inhibitor we were able to identify a tocopherol-
like molecule. This compound was assayable by the Emmerie-Engle tech-
nique. It should be remembered that the phosphate salt of alpha tocopherol
is not assayable by this technique, it being the=OH radical of the quinone
portion of the molecule which is responsible for the anti-oxidant action of
the molecule in this reaction.
We do believe that the antithrombic activity of this fraction is due to its
tocopherol content, since we have tested other salts (alpha tocopherol sul-
phate and chroman, and coumarin phosphate)* and have found that the
only effective thrombin inhibitors are those with the full tocopherol struc-
ture. These observations led us to conclude that it is the structure of the
molecule, rather than any specific chemical reaction, which accounts for its
activity, and to conclude further that if the molecule could be made water-
soluble in the form of a lipo-protein, it would retain this activity.
This will mean, however, that assayable levels of alpha tocopherol will
not appear in circulating blood following the administration of alpha toco-
pherol phosphate unless the tocopherol is hydrolyzed before or after venous
blood is withdrawn. The former is apparently not the case.
The data do not justify the conclusion that alpha tocopherol phosphate
is a normal constituent of blood or that the antithrombic effect of the
administration of alpha tocopherol phosphate reproduces a normal physio-
logical metabolic process. Epstein and Morgulis,' however, have published
data on the efficacy of alpha tocopherol phosphate in treating nutritional
muscular dystrophy in rabbits, which means that the avitaminosis responds
to therapy with tocopherol phosphate.
Further confusion concerning our work has arisen from the fact that the
antithrombin test is not entirely reliable when a commercial source of throm-
bin is used. In our original work we used 65 unit-ampules of thrombin,
which were carefully assayed. Using this particular source of thrombin,
we described a one-stage and a two-stage technique, the two tests correlat-
ing well. When, however, we began to use a commercial thrombin, which
is the only source available to most investigators, we found that the one-
stage technique, which we had reported in two published articles, was un-
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satisfactory and that the two tests no longer correlated, low values being ob-
tained more frequently with the two-stage. Above 1: 16 the correlation was
very good, but 1: 8 levels were seldom obtained with the one-stage tech-
nique, while they continued to occur when the two-stage technique was
used. The difference between the two tests is fairly simple. In the one-stage
technique, the clot is read after the thrombin is diluted and added to whole
plasma. In the two-stage technique, the plasma is diluted, a constant amount
of thrombin is added, the mixture is incubated, and fibrinogen is added to
it before the clot is read. Since amounts of thrombin in the two tests are
essentially equivalent, the fact that they do not correlate in low levels im-
mediately raises the question whether we are actually measuring an anti-
thrombin. For this reason, we are now proposing the name "prethrombotic
index" for the test which we have described. The thrombin preparations, of
course, contain various amounts of the factors necessary to convert pro-
thrombin to thrombin since the technique of preparing thrombin consists
of adsorption of prothrombin from plasma and subsequent conversion, by
the addition of calcium, thromboplastin, and greater or lesser amounts of
accelerator globulin. If the two tests correlated, it would be reasonable to
assume that the thrombin is the substance responsible for the clot produc-
tion. Since they do not, the question arises whether in the two-stage
technique we are not measuring the ability of lesser amounts of thrombo-
plastin, calcium, accelerator globulin, or thrombin to convert the prothrom-
bin in diluted plasma. At the present time we are unable to define the
exact nature of the test which we use, and we therefore feel that it would
be better to call it a prethrombotic index and to emphasize that if the test
is to be used for prediction of a prethrombotic stage, it must be done in two
stages, as follows:
1. Place in a test tube 1.4 ml. of 1.85% solution of K2CrO4.
2. Add 10 ml. of blood as soon as it is withdrawn and mix well.
3. Centrifuge at 1,500 RPM for 10 minutes.
4. Remove the supernatant plasma.
5. Make a serial dilution of the plasma, as follows:
a. Place 10 tubes in rack; add 0.5 cc. distilled H20 to all except 41.
b. Place 0.5 ml. of plasma in tube #1 (1:1).
c. Place 0.5 ml. of plasma in tube #2 and mix well (1:2).
d. Place 0.5 ml. of the mixture from tube V2 in tube X3, and mix well (1:4).
e. Continue to dilute the plasma in the manner described until 10 tubes have
been prepared. The dilution in the tenth tube is 1:512.
6. Add to each tube exactly 0.1 ml. of thrombin solution in distilled water. This
thrombin is put up in ampoules of varying concentration. Exact amount in each
ampoule (labelled 1000 units) can be determined by writing Eugene Loomis,
Parke Davis Research Laboratory, Detroit. It is diluted so that each cubic
centimeter contains 0.01 unit of thrombin.
7. Shake the tubes well, then incubate them in a water bath at 37.5° C.
8. Add to each tube 0.1 ml. of 3%o bovine fibrinogen (Armour and Co.) solution
(in distilled water). The fibrinogen must be frozen and thawed. The profibrin
which is precipitated by freezing is removed by centrifugation and discarded.
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Only the clear supernatant is used. The solution is prepared by weight and contains
40-50% sodium citrate.
9. Incubate the tubes for another 60 minutes.
10. Observe each tube for the last trace of fibrin formation, recording the greatest
dilution at which it ceases to occur. The fibrin frequently appears as a fine
precipitate occurring in decreasing amounts.
In normal plasma, fibrin formation ceases to occur when the plasma dilution is
between 1:32 and 1:128.
Evaluation of results
The data accumulated over the past two years, we believe, strongly sug-
gest that the test which we have devised actually is of value in predicting
thrombosis. Thus in 246 cases that were studied as controls, there occurred
23 cases of thrombosis or embolism, with 5 embolic deaths. All 5 patients
showed a 1: 8 level on or shortly before the day of death. In one non-fatal
instance of embolism, the 1: 8 level was not obtained, this being the only
case in our control series in which a 1: 8 level was not present when either
thrombosis or symptoms of emboli developed. Thrombosis was diagnosed
clinically in 16 cases in the series. All of these patients were submitted to
venous ligation following the diagnosis and in 8 instances, clots were found
at the time of the ligation. The diagnosis of phlebothrombosis in these cases
was made on the basis of any two of three physical findings, namely, calf
tenderness, unilateral edema, or dilation of the peripheral veins. Patients
showing only one of this triad were not considered as having phlebothrom-
bosis in this particular portion of study.
Later we broadened these criteria. In the total series of 246 cases, a
number of 1:8 levels were obtained in patients who did not develop clinical
phlebothrombosis by our criteria of diagnosis. When the prothrombin
times were analyzed in relation to the occurrence of 1: 8 levels, it was found
that only those patients who had normal or near-normal prothrombin times,
develop the clinical syndrome.
Our studies indicated that this differential in prothrombin times could
not be picked up if rabbit brain thromboplastin was used. When we used
thromboplastin from this source, which gives a very rapid prothrombin
time, a large percentage of the measurements were found to be normal
or 100 per cent. When, on the other hand, a lung thromboplastin was used,
which gave a normal control prothrombin time of approximately 16 seconds,
it was found that many of the patients showed prothrombin times of over
20 seconds.
Inthegroup of patients showing 1: 8 levels and prothrombin times longer
than 20 seconds, there was only one instance of thrombosis, a fatal case of
cerebral thrombosis confirmed at autopsy. On the other hand, in the group
of patients showing 1: 8 levels and having prothrombin times shorter than
20 seconds on the same day, 23 developed phlebothrombosis. There was
no particular day, in terms of postoperative days, on which the low levels
occurred, but it was observed that they usually preceded the occurrence of
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clinical symptoms of phlebothrombosis by 6 to 72 hours. Frequently, the
clinical syndrome had developed between the time the blood was drawn, the
levels determined, and the patients checked on the wards for possible
symptoms.
For this chronologic reason the prethrombotic index alone is not entirely
practical. Therapy cannot always be instituted before the disease occurs.
The test did, however, help us in this particular group of patients in that
we were able to ligate their veins perhaps somewhat earlier than would
have been possible had we not had information indicating the possibility
of thrombosis.
It must further be emphasized that this test must be run every day, in-
cluding Sunday, since the omission of even one day could mean that the
low level on that particular patient might be missed and the prethrombotic
state not recognized.
Our experiences with this test have thus led us to place considerable faith
in it for predicting the occurrence of thrombosis in association with a low
prethrombotic index.
Interpretation of the effect of tocopherol and calcium on the
incidence of low prethrombotic index level
The next question of interpretation is concerned with the effect of alpha
tocopherol and calcium administration on the prevention of low prethrom-
botic index levels. Our therapy consists in the administration of alpha
tocopherol phosphate in doses of 100 mg. every 8 hours until the patient
can take oral medication. After this time, 200 iu of alpha tocopherol acetate
are given daily by mouth. In addition, 10 cc. of calcium gluconate are given
every 24 hours. Medication is begun immediately after operation.
In 457 patients treated by this routine, we have found only 15 with 1: 8
levels. Statistically, no further comment seems needed. It is obvious that
the administration of tocopherol and calcium, routinely, to postoperative
patients results in a marked reduction of the incidence of low prethrombotic
index levels. The natural corollary is that if we believe the prethrombotic
index to be an efficient method of predicting thrombosis, and if we can
maintain the prethrombotic index above that certain low level which is
associated with thrombosis, then we should reduce the incidence of throm-
bosis.
This brings us to the third aspect of our work, namely, the effect of toco-
pherol and calcium on the incidence of thrombosis. To date we have
treated only 457 patients. In evaluating the incidence of thrombosis in so
small a group, it is impossible to say statistically that we have influenced
the incidence of the disease because of the great variations which are seen
from year to year. Our data show that we have had only 15 with 1: 8 levels
and that these have been associated with 5 phlebothromboses, and with two
pulmonary emboli. At the present time we consider a patient to have
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phlebothrombosis if he presents only one of the criteria which we use for
diagnosis. That is, if a patient has only edema, or dilated peripheral veins,
or calf tenderness, vein ligation is performed and he is considered to have
had a phlebothrombosis. Indeed, at the present time it is our tendency to
perform venous ligation on all 1: 8 levels if they have any complaint at all
referable to the leg. Any conclusion, however, concerning the effect of toco-
pherol and calcium on the incidence of thrombosis must await a larger
series of cases either from our own clinic or from other sources.
TABLE 1
TYPE OF PROCEDURE
Untreated control cases Treated cases
Thrombo- Thrombo-
embolism Embolic embolism Embolic
Number cases deaths Number cases deaths
Biliary tract 51 5 1 88 1
Alimentary tract
Esophageal resection 3 2
Gastric resection 37 4 69
Intestinal resection 38 5 74 1
Closure GI perforation 9 35 2 1
contributory
Chest
Pneumonectomy 22 3 2 22 1 1
Lobectomy 10 24
Chest-Exploratory
Non-malignant diseases 12 1 1 11
Malignant diseases 6 12
Abdomen-Exploratory
Non-malignant diseases 26 27
Malignant diseases 16 1 1 21
Other 18 3* 10
246 23 (8 clots) 5 395 5 (no clots) 2
* Following radical neck dissection, endaneurysmorrhaphy, and sympathectomy.
Table 1 shows the type of case we have used in our study as well as the
relative occurrence of thrombosis and embolism in 246 control and 395
treated cases. Patients submitted to sympathectomy and amputation have
only recently been treated. They were added because in the year ending
July 1, 1950 there was a significant number (5 cases) of emboli in these
groups, although the incidence in other relatively minor operative groups
remained the same.
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group, but we believe we are no longer justified in omitting prophylactic
therapy in any patient who might develop thrombo-embolism after oper-
ation. The last one hundred controls and the first one hundred treated
patients were seen simultaneously. The incidence of fatal emboli in patients
with a 1: 8 level who had no peripheral sign of thrombosis was 2 per cent
in our series, which was high enough to make us think that therapy was
needed in all instances of possible thrombo-embolism. The risk of Dicumarol
is too great to justify its use on surgical wards, particularly on wards
where control and accurate following of prothrombin times is impossible.
Moreover, even admitting the practicality of the routine use of anticoagu-
lants during the postoperative period, such a group would not serve as a
control on the incidence of thrombosis and embolism. It would merely
permit comparison with the effectiveness of tocopherol and calcium. Since
we know something of the dangers of routine Dicumarol prophylaxis,
we did not feel that the use of such a group would add significance to our
studies or reduce the overall mortality significantly. For these reasons, we
now chose to compile our data in terms of a large group of patients, all of
whom receive tocopherol and calcium prophylactically.
Summary
Studies have shown that antithrombic activity of the calcium salt of alpha
tocopherol is significant in terms of variations in the level of the prethrom-
botic index.
A low level (1: 8) as measured by the prethrombotic index is associated
with a high incidence of thrombosis if, when this level is obtained, the
prothrombin time of the patient is at or near normal.
The administration of tocopherol and calcium in prescribed amounts and
by prescribed routes is associated with a marked reduction in the incidence
of low prethrombotic index levels.
It is conceivable, though not yet proved statistically, that the administra-
tion of alpha tocopherol and calcium will reduce the incidence of post-
operative phlebothrombosis and pulmonary embolism.
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